{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:41:51Z","timestamp":1791999711712,"version":"4.4.0"},"reference-count":57,"publisher":"American Medical Association (AMA)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"DOI":"10.1001\/jamanetworkopen.2022.0194","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T16:37:25Z","timestamp":1645720645000},"page":"e220194","source":"Crossref","is-referenced-by-count":23,"title":["Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors"],"prefix":"10.1001","volume":"5","author":[{"given":"Ismaeel","family":"Yunusa","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Center for Outcomes Research and Evaluation, Department of Clinical Pharmacy and Outcomes Sciences, University of South Carolina College of Pharmacy, Columbia"},{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Gagne","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"},{"name":"Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Inflammation, and Immunity, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsiaryna","family":"Bykov","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"issue":"12","key":"zoi220019r1","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2021.1169","article-title":"Continued increases in overdose deaths related to synthetic opioids: implications for clinical practice.","volume":"325","author":"Baldwin","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"zoi220019r2","doi-asserted-by":"publisher","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","article-title":"Drug and opioid-involved overdose deaths\u2014United States, 2017-2018.","volume":"69","author":"Wilson","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"5152","key":"zoi220019r3","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.15585\/mmwr.mm675152e1","article-title":"Drug and opioid-involved overdose deaths\u2014United States, 2013\u20132017.","volume":"67","author":"Scholl","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"6","key":"zoi220019r4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and geographic patterns in drug and synthetic opioid overdose deaths\u2014United States, 2013-2019.","volume":"70","author":"Mattson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"23","key":"zoi220019r8","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1056\/NEJMra1807054","article-title":"Prevention of opioid overdose.","volume":"380","author":"Babu","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi220019r9","first-page":"1","article-title":"Drugs most frequently involved in drug overdose deaths: United States, 2010-2014.","volume":"65","author":"Warner","year":"2016","journal-title":"Natl Vital Stat Rep"},{"issue":"9","key":"zoi220019r10","first-page":"1","article-title":"Drugs most frequently involved in drug overdose deaths: United States, 2011-2016.","volume":"67","author":"Hedegaard","year":"2018","journal-title":"Natl Vital Stat Rep"},{"key":"zoi220019r11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/DHPS","article-title":"Concomitant use of opioid medications with triptans or serotonergic antidepressants in US office-based physician visits.","volume":"10","author":"Molina","year":"2018","journal-title":"Drug Healthc Patient Saf"},{"issue":"20","key":"zoi220019r13","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1001\/archinte.163.20.2433","article-title":"Depression and pain comorbidity: a literature review.","volume":"163","author":"Bair","year":"2003","journal-title":"Arch Intern Med"},{"issue":"2","key":"zoi220019r14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210575","article-title":"Predicting inadequate postoperative pain management in depressed patients: a machine learning approach.","volume":"14","author":"Parthipan","year":"2019","journal-title":"PLoS One"},{"issue":"1-2","key":"zoi220019r15","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.pain.2003.10.009","article-title":"Depression as a risk factor for onset of an episode of troublesome neck and low back pain.","volume":"107","author":"Carroll","year":"2004","journal-title":"Pain"},{"issue":"9","key":"zoi220019r16","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1017\/S0033291705004952","article-title":"More data on major depression as an antecedent risk factor for first onset of chronic back pain.","volume":"35","author":"Currie","year":"2005","journal-title":"Psychol Med"},{"issue":"2","key":"zoi220019r17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1017\/S0033291703001041","article-title":"Depressive disorder as a long-term antecedent risk factor for incident back pain: a 13-year follow-up study from the Baltimore Epidemiological Catchment Area sample.","volume":"34","author":"Larson","year":"2004","journal-title":"Psychol Med"},{"issue":"1","key":"zoi220019r19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2174\/1389200023338017","article-title":"Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update.","volume":"3","author":"Hemeryck","year":"2002","journal-title":"Curr Drug Metab"},{"key":"zoi220019r21","first-page":"S276","article-title":"Opioid pharmacokinetic drug-drug interactions.","volume":"17","author":"Overholser","year":"2011","journal-title":"Am J Manag Care"},{"key":"zoi220019r22","doi-asserted-by":"crossref","first-page":"i5014","DOI":"10.1136\/bmj.i5014","article-title":"Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study.","volume":"354","author":"Donneyong","year":"2016","journal-title":"BMJ"},{"issue":"6","key":"zoi220019r24","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s40262-018-00731-3","article-title":"Updated clinical pharmacokinetics and pharmacodynamics of oxycodone.","volume":"58","author":"Kinnunen","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"zoi220019r25","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jpainsymman.2012.08.013","article-title":"Opioid therapies and cytochrome p450 interactions.","volume":"44","author":"Gudin","year":"2012","journal-title":"J Pain Symptom Manage"},{"key":"zoi220019r26","doi-asserted-by":"publisher","first-page":"S26","DOI":"10.1111\/j.1526-4637.2011.01134.x","article-title":"An analysis of the root causes for opioid-related overdose deaths in the United States.","volume":"12","author":"Webster","year":"2011","journal-title":"Pain Med"},{"issue":"4","key":"zoi220019r27","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/j.1476-5381.2010.00673.x","article-title":"The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.","volume":"160","author":"Samer","year":"2010","journal-title":"Br J Pharmacol"},{"issue":"6","key":"zoi220019r28","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40265-013-0036-0","article-title":"Cytochrome P450-mediated changes in oxycodone pharmacokinetics\/pharmacodynamics and their clinical implications.","volume":"73","author":"S\u00f6derberg L\u00f6fdal","year":"2013","journal-title":"Drugs"},{"issue":"1","key":"zoi220019r29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/bcp.2010.70.issue-1","article-title":"Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone.","volume":"70","author":"Gr\u00f6nlund","year":"2010","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"zoi220019r30","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/pds.3891","article-title":"Guidelines for good pharmacoepidemiology practice (GPP).","volume":"25","author":"Public Policy Committee, International Society of Pharmacoepidemiology","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"zoi220019r31","doi-asserted-by":"crossref","first-page":"k3532","DOI":"10.1136\/bmj.k3532","article-title":"The Reporting of Studies Conducted Using Observational Routinely Collected Health Data Statement for Pharmacoepidemiology (RECORD-PE).","volume":"363","author":"Langan","year":"2018","journal-title":"BMJ"},{"issue":"8","key":"zoi220019r32","doi-asserted-by":"publisher","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"issue":"4","key":"zoi220019r33","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/acem.13121","article-title":"Performance measures of diagnostic codes for detecting opioid overdose in the emergency department.","volume":"24","author":"Rowe","year":"2017","journal-title":"Acad Emerg Med"},{"issue":"7","key":"zoi220019r34","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A combined comorbidity score predicted mortality in elderly patients better than existing scores.","volume":"64","author":"Gagne","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"zoi220019r35","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/EDE.0000000000000627","article-title":"Matching weights to simultaneously compare three treatment groups: comparison to three-way matching.","volume":"28","author":"Yoshida","year":"2017","journal-title":"Epidemiology"},{"key":"zoi220019r36","doi-asserted-by":"crossref","first-page":"l5657","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners.","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"issue":"15","key":"zoi220019r37","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1001\/jama.2015.13480","article-title":"The propensity score.","volume":"314","author":"Haukoos","year":"2015","journal-title":"JAMA"},{"issue":"17","key":"zoi220019r38","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1001\/jama.2016.16435","article-title":"Confounding by indication in clinical research.","volume":"316","author":"Kyriacou","year":"2016","journal-title":"JAMA"},{"issue":"3","key":"zoi220019r39","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"issue":"10","key":"zoi220019r40","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1001\/jama.2016.1825","article-title":"Time-to-event analysis.","volume":"315","author":"Tolles","year":"2016","journal-title":"JAMA"},{"issue":"6","key":"zoi220019r41","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1097\/EDE.0b013e3181875e61","article-title":"Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease.","volume":"19","author":"Hern\u00e1n","year":"2008","journal-title":"Epidemiology"},{"key":"zoi220019r42","article-title":"Standards for causal inference methods in analyses of data from observational and experimental studies in patient-centered outcomes research.","author":"Gagne","year":"2012"},{"issue":"3","key":"zoi220019r43","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2165\/11539950-000000000-00000","article-title":"Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone.","volume":"31","author":"Gr\u00f6nlund","year":"2011","journal-title":"Clin Drug Investig"},{"issue":"1","key":"zoi220019r44","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s00228-010-0893-3","article-title":"Effect of the inhibition of CYP3A4 or CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.","volume":"67","author":"Kummer","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"zoi220019r45","doi-asserted-by":"publisher","first-page":"35","DOI":"10.9740\/mhc.2016.01.035","article-title":"A review of significant pharmacokinetic drug interactions with antidepressants and their management.","volume":"6","author":"Hoffelt","year":"2016","journal-title":"Ment Health Clin"},{"issue":"5","key":"zoi220019r46","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.clpt.2006.01.009","article-title":"Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.","volume":"79","author":"Lalovic","year":"2006","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"zoi220019r47","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/S0009-9236(96)90024-7","article-title":"Pharmacokinetic-pharmacodynamic relationships of controlled-release oxycodone.","volume":"59","author":"Kaiko","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"zoi220019r48","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2147\/JPR","article-title":"Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management.","volume":"10","author":"Feng","year":"2017","journal-title":"J Pain Res"},{"issue":"3","key":"zoi220019r49","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/jat\/bku007","article-title":"Observations of urinary oxycodone and metabolite distributions in pain patients.","volume":"38","author":"Elder","year":"2014","journal-title":"J Anal Toxicol"},{"issue":"8","key":"zoi220019r52","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1200\/JCO.2000.18.8.1780","article-title":"Drug interactions in palliative care.","volume":"18","author":"Bernard","year":"2000","journal-title":"J Clin Oncol"},{"issue":"7","key":"zoi220019r53","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/jamainternmed.2020.0989","article-title":"Trends in utilization of prescribed controlled substances in US commercially insured adults, 2004-2019.","volume":"180","author":"Bykov","year":"2020","journal-title":"JAMA Intern Med"},{"issue":"3","key":"zoi220019r55","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/cpt.1057","article-title":"Genomic variation and pharmacokinetics in old age: a quantitative review of age- vs. genotype-related differences.","volume":"105","author":"D\u00fccker","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"zoi220019r56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060239","article-title":"CYP2D6 genotype dependent oxycodone metabolism in postoperative patients.","volume":"8","author":"Stamer","year":"2013","journal-title":"PLoS One"},{"issue":"4","key":"zoi220019r57","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/dom.2018.20.issue-4","article-title":"Claims-based studies of oral glucose-lowering medications can achieve balance in critical clinical variables only observed in electronic health records.","volume":"20","author":"Patorno","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"zoi220019r5","unstructured":"US Centers for Disease Control and Prevention (CDC). Wide-ranging online data for epidemiologic research (WONDER). Accessed July 15, 2021. http:\/\/wonder.cdc.gov"},{"key":"zoi220019r6","unstructured":"US Centers for Disease Control and Prevention (CDC). Prescription opioid overdose death maps. Accessed on July 15, 2021. https:\/\/www.cdc.gov\/drugoverdose\/deaths\/prescription\/maps.html"},{"key":"zoi220019r7","unstructured":"HHS.gov. US Surgeon General\u2019s advisory on naloxone and opioid overdose. Accessed July 29, 2021. https:\/\/www.hhs.gov\/surgeongeneral\/priorities\/opioids-and-addiction\/naloxone-advisory\/index.html"},{"key":"zoi220019r12","doi-asserted-by":"crossref","unstructured":"Perananthan? V, Buckley? N. Opioids and antidepressants: which combinations to avoid.? Aust Prescr. 2021;44:41-44. doi:10.18773\/austprescr.2021.004","DOI":"10.18773\/austprescr.2021.004"},{"key":"zoi220019r18","unstructured":"IQVIA Institute for Human Data Science. Medicine use and spending in the US: a review of 2017 and outlook to 2020. Accessed July 29, 2021. https:\/\/www.iqvia.com\/-\/media\/iqvia\/pdfs\/institute-reports\/medicine-use-and-spending-in-the-us-a-review-of-2017-and-outlook-to-2022.pdf?_=1549160094009"},{"key":"zoi220019r20","unstructured":"Brown? CH. Overview of drug-drug interactions with SSRIs. US Pharmacist. January 23, 2008. Accessed January 25, 2022. https:\/\/www.uspharmacist.com\/article\/overview-of-drugdrug-interactions-with-ssris"},{"key":"zoi220019r23","unstructured":"Indiana University. Drug interactions Flockhart table. Accessed December 30, 2021. https:\/\/drug-interactions.medicine.iu.edu\/MainTable.aspx"},{"key":"zoi220019r50","unstructured":"Australian Government Department of Health Therapeutic Goods Administration. Australian public assessment report for oxycodone\/naloxone. Accessed June 1, 2021. https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-oxycodone-170607.docx"},{"key":"zoi220019r51","unstructured":"OxyContin Package Insert. Purdue Pharma. Accessed June 1, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/020553s059lbl.pdf"},{"key":"zoi220019r54","doi-asserted-by":"crossref","unstructured":"Hedegaard? H, Mini\u00f1o? AM, Spencer? MR, Warner? M. Drug overdose deaths in the United States, 1999\u20132020.? NCHS Data Brief, No. 428. National Center for Health Statistics. December 2021. doi:10.15620\/cdc:112340","DOI":"10.15620\/cdc:112340"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2789401\/yunusa_2022_oi_220019_1645038641.42337.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T16:37:41Z","timestamp":1645720661000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2789401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.0194","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]}}}